We are here to provide you with answers to any questions you may have in relation to the AAV9 screening. At Cerba Research we are operational 7 days a week, including bank holidays, in order to provide continuous support as well as testing and reporting.
Important Update regarding contact
VIROCLINICS NAME & EMAIL CHANGE
From Monday 10 July 2023, emails sent to AAV9-Screening@viroclinics.com will be forwarded automatically to our new email address: AAV9-Screening@cerbaresearch.com
You will then get reply emails from our new email address. We also encourage you to use this new email after Monday, 10 July 2023.
Cerba Research
Viroclinics‑DDL officially became part of Cerba Research in 2022. The acquisition of Viroclincs unified its Netherlands‑based specialty laboratories and global partner network under Cerba Research’s mission to advance clinical research. This important addition strengthens Cerba Research’s ability to provide end‑to‑end virology, vaccine, and broader clinical trial solutions worldwide.